CLEVIPREX® (clevidipine) has individualized, titratable dosing and administration
Low-volume, non-weight-based dosing1
- Administered intravenously by a dedicated central or a dedicated peripheral line
- Single-use parenteral emulsion* that contains 0.005% EDTA to inhibit the rate of growth of microorganisms for up to 12 hours
- Metabolized by esterases in the blood and extravascular tissues
- Elimination is unlikely to be affected by hepatic or renal dysfunction
*CLEVIPREX contains approximately 0.2g of lipid per mL (2.0 kcal).
Dosage forms and strengths
- 50 mL and 100 mL single-use vials
- Concentration: 0.5 mg/mL
Individualized, titratable administration1
- Initiate intravenous CLEVIPREX infusion at 1–2 mg/hr (2–4 mL/hr)
- This includes patients with abnormal hepatic function and moderate to severe renal impairment
- Individualized dosage depending on the response of the patient and the BP goal
- Most patients were treated with maximum doses of 16 mg/hr or less
Must enter a whole number.
Please enter a whole number between 1‑32.
Must enter a whole number.
Please enter an even number between 2‑64.
- Dose may be doubled every 90 seconds initially
- As BP approaches goal:
- Increase dose by less than double
- Lengthen time between dose adjustments to every 5–10 minutes
- An approximately 1–2 mg/hr (2–4 mL/hr) increase will generally produce an additional 2–4 mmHg decrease in SBP
- Most patients achieve desired therapeutic response at 4–6 mg/hr (8–12 mL/hr)
- Severe hypertension may require doses up to 32 mg/hr (64 mL/hr), but there is limited experience at this dose rate
- Monitor blood pressure and heart rate continually during infusion, and then until vital signs are stable
- Patients who receive prolonged CLEVIPREX infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped. These patients may need follow-up adjustments in BP control
- Most patients treated with maximum doses of 16 mg/hr (32 mL/hr) or less
- There is limited short-term experience with doses as high as 32 mg/hr (64 mL/hr)
- Because of lipid load restrictions, no more than 1,000 mL or an average of 21 mg/hr (42 mL/hr) of CLEVIPREX infusion is recommended per 24-hour period
- There is little experience with infusion durations beyond 72 hours at any dose
Optimizing CLEVIPREX administration1
- Maintain strict aseptic technique
- Inspect package and bottle for any defects and bottle contents for particulate matter, discoloration, or contaminants; do not use if contamination is suspected
- Invert vial gently several times before use to ensure uniformity of the emulsion
- Once stopper is punctured, use within 12 hours and discard any unused portion
- Because CLEVIPREX is a low-volume infusion, it is crucial to prime the IV tubing and check for dead space
- Manage lack of response
- Ensure CLEVIPREX is getting to the patient by checking for dead space
- Individual patient response may vary
- Note rapid onset and offset of CLEVIPREX when changing the IV set or vial
Watch the CLEVIPREX dosing and administration video
Watch the whole video, or select a chapter for more specific information.